Current News

Print version | Send article | RSS feed

Eden Biodesign and ImmunoBiology (ImmBio) develop next generation vaccine for the prevention of influenza

21 Mar 2007 - Eden Biodesign Ltd, provider of development and manufacturing services for new medicines, announced that it has been selected by ImmunoBiology Limited (ImmBio), a biotechnology company developing the next generation of anti-infective vaccines, to provide a range of development and manufacturing services for their leading influenza vaccine programme. This targets both seasonal and pandemic flu, where manufacturing speed and flexibility is critical to meet unmet market needs.
 
Graham Clarke, CEO of ImmBio said: "Working with Eden Biodesign will allow us to rapidly advance the next generation influenza vaccine forward towards a Clinical Trial Application and is consistent with our aggressive timelines for bringing our viral lead product to the clinic. We are delighted for the development of our leading influenza programme to be managed by Eden Biodesign at their state of the art facility in Liverpool."